Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2 -negative breast cancer.

Oct 7, 2024 · Palbociclib may be used to treat HR-positive, HER2-negative advanced or metastatic breast cancer in adults. Your doctor will prescribe it for you if it has a proven benefit for your type of …

Jan 28, 2026 · On the basis of preclinical and clinical data, the addition of palbociclib (a selective inhibitor of cyclin-dependent kinases 4 and 6) may overcome resistance to both endocrine and HER2 …

Palbociclib stops cancer cells from growing. It treats breast cancer, which occurs when cells in your breast grow and divide in an uncontrolled way.

Mar 1, 2026 · Palbociclib can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. If you can, avoid people with infections.

Jul 10, 2024 · Find patient medical information for Ibrance (palbociclib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

Palbociclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Blocking these proteins may slow or stop the growth of cancer cells.

Palbociclib is used in combination with another medication as an initial treatment for a certain type of hormone receptor–positive, advanced breast cancer (breast cancer that depends on hormones such …

Feb 21, 2024 · Palbociclib (Ibrance) is a targeted cancer drug treatment for breast cancer. Find out how you have it, possible side effects and other important information.

May 14, 2015 · Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast …